TIANJIN, China, Nov. 17, 2020 /PRNewswire/ — SINOMED® today announced that Prof. Alexandra Lansky from the Yale School of Medicine, USA, presented data from its first inter-continental PIONEER III study comparing the safety and efficacy of the Supreme HT (Healing-Targeted) Drug-Eluting Stent, to the Xience or Promus Durable Polymer Drug-Eluting Stent (DP DES). One-year results, revealed […]
Other News
INFINITY ANGIOPLASTY BALLOON CATHETER™ Completes First-In-Human PRECISION ANGIOPLASTY™
TOLEDO, Ohio, Nov. 17, 2020 /PRNewswire/ — INFINITY ANGIOPLASTY BALLOON CO., announced today that its innovative PRECISION ANGIOPLASTY™ balloon platform – INFINITY ANGIOPLASTY BALLOON CATHETER™ has successfully completed First-in-Human clinical trial. Recently cleared by the FDA for PTA treatment of peripheral artery disease including: iliac femoral popliteal infra-popliteal arteries for the treatment of […]
Results From SOLOIST and SCORED Outcomes Studies Presented at Late-Breaking Science Session of American Heart Association Scientific Sessions and Published in The New England Journal of Medicine
Sotagliflozin Significantly Reduced Total Cardiovascular Deaths, Heart Failure Hospitalization and Urgent Visits, Achieving Primary Endpoint in Both Studies THE WOODLANDS, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints by demonstrating statistically significant reductions […]
SANUWAVE Health Reports Third Quarter 2020 Financial Results
Transformational Acquisition Positions for Significant Growth in Fourth Quarter 2020 and Beyond SUWANEE, GA, Nov. 17, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — SANUWAVE Health, Inc. (OTCQB: SNWV), focused on the development and commercialization of a robust and innovative advanced wound care product portfolio for the repair and regeneration of skin and vascular structures, […]
Biotricity Reports Results for the Quarter Ended September 30, 2020
Revenues grow 64.8% over the immediately preceding quarter and a 115.3% increase over the corresponding period of the prior year Loss per share of 8.5 cents in line with levels of immediately preceding quarter REDWOOD CITY, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and […]
Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company’s Leading Cardiovascular Franchise
NEW YORK–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of MyoKardia, Inc. in an all cash transaction for approximately $13.1 billion. With the completion of the acquisition, MyoKardia shares have ceased trading on the NASDAQ Global Select Market and MyoKardia is now a wholly-owned subsidiary […]
Bayer Presents FIDELIO-DKD Phase III Study Cardiovascular Subgroup Analysis of Patients With Chronic Kidney Disease and Type 2 Diabetes
Late-breaking data presented at AHA 2020 Scientific Sessions and published simultaneously in Circulation WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer announced today late-breaking data from a pre-specified exploratory subgroup analysis of the FIDELIO-DKD Phase III study, in which the investigational drug finerenone, compared to placebo, reduced the risk of cardiovascular (CV) outcomes in patients with […]
TISSIUM Receives FDA Investigational Device Exemption for Vascular Sealant
IDE Approval Clears Path to U.S. Clinical Trial Launch for Vascular Sealant PARIS–(BUSINESS WIRE)–TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has received approval from the U.S. Food and Drug Administration for its Investigational Device Exemption application for its vascular sealant. The approval […]
Tenax Therapeutics Reports Third Quarter 2020 Results and Provides Business Update
MORRISVILLE, N.C.–(BUSINESS WIRE)–Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today reported financial results for the third quarter 2020 and provided a business update. Tenax will share updates related to levosimendan and its recently completed Phase 2 […]
PhysioStim appoints Dr. Bruno Le Grand as scientific advisor
Preclinical CRO will enhance its pharmacology research services and reinforce its commercial offering to address the growing needs of the cardiovascular and safety markets Lautrec, France November 17, 2020 – PhysioStim, a preclinical CRO specialized in cardiac electrophysiology, today announces the appointment of Dr. Bruno Le Grand as scientific advisor. Dr. […]



